The risk/ benefit ratio of Lansopon 15 mg, 30 mg is considered to be favourable provided that appropriate information regarding H. pylori eradication therapy are included in the SPC.
Lansopon 15 mg, 30 mg udviser et gunstigt benefit/ risk- forhold, forudsat at der indføjes passende oplysninger vedrørende eradikationsbehandlingen for H. pylori i produktresuméet.